FDA approves drug for postmenopausal symptoms
The first drug combining estrogens with bazedoxifene has been approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.
The first drug combining estrogens with bazedoxifene has been approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.
Produced by Wyeth Pharmaceuticals, Duavee is indicated only for postmenopausal women who still have their uterus. Bazodoxifene reduces the risk of endometrial hyperplasia.
The FDA advises that clinicians prescribe Duavee for the shortest period of time that will meet treatment needs. It can be given solely to prevent osteoporosis, but the indication is only for women at serious risk of losing bone mass and strength and after careful consideration of other non-estrogen drugs.
Common adverse effects observed during clinical trials with estrogen plus bazedoxifene included muscle spasm, nausea, diarrhea, dyspepsia, upper abdominal pain, oropharyngeal pain, dizziness, and neck pain. The drug will carry the same boxed warnings as other approved estrogen drugs.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More
Study shows hormone therapy offers lasting benefits for women over 65
September 12th 2024A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.
Read More
